Thomas DiRaimondo
Chief Tech/Sci/R&D Officer bei JANUX THERAPEUTICS, INC.
Vermögen: 4 Mio $ am 31.03.2024
Profil
Thomas DiRaimondo is the founder of Sitari Pharma, Inc. (founded in 2013).
He is currently working as the Chief Scientific Officer at Janux Therapeutics, Inc. since 2018.
Dr. DiRaimondo has a doctorate degree from Stanford University and undergraduate and graduate degrees from the University of Michigan.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
JANUX THERAPEUTICS, INC.
0,20% | 02.01.2024 | 101 532 ( 0,20% ) | 4 Mio $ | 31.03.2024 |
Aktive Positionen von Thomas DiRaimondo
Unternehmen | Position | Beginn |
---|---|---|
JANUX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.05.2018 |
Ehemalige bekannte Positionen von Thomas DiRaimondo
Unternehmen | Position | Ende |
---|---|---|
Sitari Pharma, Inc.
Sitari Pharma, Inc. BiotechnologyHealth Technology Sitari Pharma, Inc. provides pharmaceutical research and development services. It engages in multiple disease indications such as celiac disease. The company was founded by Chaitan S. Khosla and Thomas DiRaimondo in 2013 and is headquartered in La Jolla, CA. | Founder | 01.08.2019 |
Ausbildung von Thomas DiRaimondo
Stanford University | Doctorate Degree |
University of Michigan | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
JANUX THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Sitari Pharma, Inc.
Sitari Pharma, Inc. BiotechnologyHealth Technology Sitari Pharma, Inc. provides pharmaceutical research and development services. It engages in multiple disease indications such as celiac disease. The company was founded by Chaitan S. Khosla and Thomas DiRaimondo in 2013 and is headquartered in La Jolla, CA. | Health Technology |